Deutsche Bank
INDV icon

Deutsche Bank’s Indivior Pharmaceuticals INDV Stock Holding History

Deutsche Bank’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.55M Sell
184,082
-29,998
-14% -$1.09M ﹤0.01% 1166
2026
Q1 		$6.53M Sell
214,080
-175,004
-45% -$5.78M ﹤0.01% 1190
2025
Q4 		$14M Buy
389,084
+282,889
+266% +$8.64M ﹤0.01% 983
2025
Q3 		$2.56M Sell
106,195
-254,693
-71% -$5.33M ﹤0.01% 1636
2025
Q2 		$5.32M Buy
360,888
+93,911
+35% +$1.09M ﹤0.01% 1215
2025
Q1 		$2.54M Sell
266,977
-21,496
-7% -$226K ﹤0.01% 1591
2024
Q4 		$3.59M Buy
288,473
+35,953
+14% +$370K ﹤0.01% 1501
2024
Q3 		$2.46M Buy
252,520
+37,400
+17% +$438K ﹤0.01% 1627
2024
Q2 		$3.47M Buy
215,120
+31,488
+17% +$568K ﹤0.01% 1378
2024
Q1 		$3.93M Buy
183,632
+28,198
+18% +$530K ﹤0.01% 1361
2023
Q4 		$2.37M Buy
155,434
+17,533
+13% +$311K ﹤0.01% 1596
2023
Q3 		$3.18M Buy
+137,901
New +$3.14M ﹤0.01% 1182

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank's INDV Position: Q2 2026 in Review

Deutsche Bank reduced its Indivior Pharmaceuticals (INDV) stake by 14% in Q2 2026, selling an estimated $1.09M and leaving 184,082 shares worth $7.55M. The position accounts for ﹤0.01% of the portfolio, ranked #1166.

Deutsche Bank first reported a position in INDV in Q3 2023 and has held it in 12 quarters since. The position peaked at $14M in Q4 2025. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Deutsche Bank held 184,082 shares of Indivior Pharmaceuticals worth $7.55M as of Q2 2026.
  • Deutsche Bank sold 29,998 Indivior Pharmaceuticals shares in Q2 2026, an estimated $1.09M.
  • Indivior Pharmaceuticals made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #1166 holding.
  • Deutsche Bank first reported a position in Indivior Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Deutsche Bank's Indivior Pharmaceuticals position peaked at $14M in Q4 2025.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.